Background: Immunoglobulin E (IgE) mediated food allergy is a potentially life-threatening condition and represents a heavy burden for patients and their families. Identification of the most suitable way for management of each patient has currently become the primary goal for physicians. Methods: This study reviewed the current literature related to IgE-mediated food allergy. Results: The use of innovative diagnostic tools, such as allergen-specific IgG4 determination, basophil activation test, and component-resolved diagnostics, is currently available to facilitate a proper diagnosis of food allergy. After several decades of "passive clinical management" of the disease, which was based only on avoidance of the allergenic food and the use of epinephrine in the event of anaphylaxis, there has been a switch to active treatment. The most recent evidence-practice guidelines strongly recommend the use of immunotherapy as an effective therapeutic option, particularly in cases of allergy to cow's milk, egg, or peanut. The use of omalizumab, in association with immunotherapy or alone, has been tested in several studies, and results on its effectiveness seemed to be encouraging. Other biologics, such as dupilumab, reslizumab, mepolizumab, and other anticytokines therapies, are being investigated. Another interesting future treatment strategy could be the use of DNA vaccines. Conclusion: In recent years, the management of IgE-mediated food allergy has greatly improved. Knowledge of pathogenetic mechanisms, understanding of the disease course, and the introduction of novel biomarkers led to more accurate diagnoses along with the active treatment of patients.
Background: Immunoglobulin E (IgE) mediated food allergy is a potentially life-threatening condition and represents a heavy burden for patients and their families. Identification of the most suitable way for management of each patient has currently become the primary goal for physicians. Methods: This study reviewed the current literature related to IgE-mediated food allergy. Results: The use of innovative diagnostic tools, such as allergen-specific IgG4 determination, basophil activation test, and component-resolved diagnostics, is currently available to facilitate a proper diagnosis of food allergy. After several decades of "passive clinical management" of the disease, which was based only on avoidance of the allergenic food and the use of epinephrine in the event of anaphylaxis, there has been a switch to active treatment. The most recent evidence-practice guidelines strongly recommend the use of immunotherapy as an effective therapeutic option, particularly in cases of allergy to cow's milk, egg, or peanut. The use of omalizumab, in association with immunotherapy or alone, has been tested in several studies, and results on its effectiveness seemed to be encouraging. Other biologics, such as dupilumab, reslizumab, mepolizumab, and other anticytokines therapies, are being investigated. Another interesting future treatment strategy could be the use of DNA vaccines. Conclusion: In recent years, the management of IgE-mediated food allergy has greatly improved. Knowledge of pathogenetic mechanisms, understanding of the disease course, and the introduction of novel biomarkers led to more accurate diagnoses along with the active treatment of patients.
Authors: Andrea Vereda; Marianne van Hage; Staffan Ahlstedt; Maria Dolores Ibañez; Javier Cuesta-Herranz; Jenny van Odijk; Magnus Wickman; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2010-11-18 Impact factor: 10.793
Authors: Odelya E Pagovich; Bo Wang; Maria J Chiuchiolo; Stephen M Kaminsky; Dolan Sondhi; Clarisse L Jose; Christina C Price; Sarah F Brooks; Jason G Mezey; Ronald G Crystal Journal: J Allergy Clin Immunol Date: 2016-06-29 Impact factor: 10.793
Authors: Alexandra F Santos; Abdel Douiri; Natalia Bécares; Shih-Ying Wu; Alick Stephens; Suzana Radulovic; Susan M H Chan; Adam T Fox; George Du Toit; Victor Turcanu; Gideon Lack Journal: J Allergy Clin Immunol Date: 2014-07-25 Impact factor: 10.793
Authors: Laurian Zuidmeer-Jongejan; Hans Huber; Ines Swoboda; Neil Rigby; Serge A Versteeg; Bettina M Jensen; Suzanne Quaak; Jaap H Akkerdaas; Lars Blom; Juan Asturias; Carsten Bindslev-Jensen; Maria L Bernardi; Michael Clausen; Rosa Ferrara; Martina Hauer; Jet Heyse; Stephan Kopp; Marek L Kowalski; Anna Lewandowska-Polak; Birgit Linhart; Bernhard Maderegger; Bernard Maillere; Adriano Mari; Alberto Martinez; E N Clare Mills; Angela Neubauer; Claudio Nicoletti; Nikolaos G Papadopoulos; Antonio Portoles; Ville Ranta-Panula; Sara Santos-Magadan; Heidi J Schnoor; Sigurveig T Sigurdardottir; Per Stahl-Skov; George Stavroulakis; Georg Stegfellner; Sonia Vázquez-Cortés; Marianne Witten; Frank Stolz; Lars K Poulsen; Montserrat Fernandez-Rivas; Rudolf Valenta; Ronald van Ree Journal: Int Arch Allergy Immunol Date: 2015-02-28 Impact factor: 2.749